News &amp; Updates

Young patients with newly diagnosed systemic lupus erythematosus (SLE) are vulnerable to psychiatric comorbidity, which tends to increase healthcare utilization, according to a study.

Psychiatric comorbidity boosts healthcare use in youth with newly diagnosed SLE

09 Feb 2023

Novel device safely delivers therapeutic compound in the colon

09 Feb 2023 by

Use of a novel drug delivery system (DDS) to deliver a therapeutic compound in the colon has been successful, achieving the intended function with no serious adverse events, reports a study presented at the recent Crohn’s & Colitis Congress (CCC 2023).

Novel device safely delivers therapeutic compound in the colon

Anti-MDA5 antibody–positive dermatomyositis with anti-Ro52 ups ILD, mortality risks

Patients with dermatomyositis (DM) who are positive for antimelanoma differentiation-associated gene 5 antibody (anti-MDA5) are more likely to have anti-Ro52 antibodies as well, and such coexistence appears to heighten the risks of rapidly progressive interstitial lung disease (ILD) and mortality, suggests a recent study.

Anti-MDA5 antibody–positive dermatomyositis with anti-Ro52 ups ILD, mortality risks

Gluten-free diet adherence suboptimal in individuals with celiac disease–IBD overlap

09 Feb 2023 by

Adherence to gluten-free diet (GFD) in individuals with celiac disease and inflammatory bowel disease (IBD) appears to be low, according to a study.

Gluten-free diet adherence suboptimal in individuals with celiac disease–IBD overlap

Blinatumomab-chemo boosts survival in MRD-negative B-lineage ALL

The addition of blinatumomab to chemotherapy extended overall survival (OS) in adults with measurable residual disease (MRD)-negative B-lineage acute lymphoblastic leukaemia (ALL), according to results of the phase III ECOG-ACRIN E1910 trial.

Blinatumomab-chemo boosts survival in MRD-negative B-lineage ALL

Biologic agents raise IBD risk among axSpA patients

Based on observational studies, patients with axial spondyloarthritis (axSpA) treated with biologics are at higher risk of inflammatory bowel disease (IBD), while findings from randomized controlled trials (RCTs) suggest that treatment with etanercept (ETN) tends to increase such risk compared to other antitumour necrosis factor (anti-TNF) therapies, according to the result of a meta-analysis.

Biologic agents raise IBD risk among axSpA patients

08 Feb 2023

Severe disease, short induction course up UC flare risk after tofacitinib dose de-escalation

Ulcerative colitis (UC) flare at 12 months has occurred in more than half of UC patients with tofacitinib dose de-escalation, according to a study presented at the recent Crohn’s & Colitis Congress (CCC 2023). Factors associated with UC flare following de-escalation are shorter induction course (<16 weeks) and active disease at 6 months of tofacitinib.

Severe disease, short induction course up UC flare risk after tofacitinib dose de-escalation

Does dexamethasone induce myocardial injury after TKA?

Use of dexamethasone has no effect on postoperative concentration of cardiac troponin I (TnI) or T (TnT) on the first postoperative morning after total knee arthroplasty (TKA), suggests a recent study.

Does dexamethasone induce myocardial injury after TKA?

Early rehab makes a difference for children with cancer

Participating in an individualized rehabilitation program is beneficial to children with cancer, yielding significant gains in function without any adverse consequences, as reported in a study from Singapore.

Early rehab makes a difference for children with cancer

Photobiomodulation promising in mild cognitive impairment

A small case series from the Chinese University of Hong Kong suggests that transcranial photobiomodulation (tPBM) may improve frontal lobe cognitive functions and mental health of older adults (OAs) with mild cognitive impairment (MCI).

Photobiomodulation promising in mild cognitive impairment